Could a Single Vaccine Prevent Colds, Flu… and Potentially Legionnaires’ Disease?
Researchers at Stanford University have announced promising early results in the development of a so-called universal vaccine designed to provide broad protection against multiple respiratory pathogens. Animal trials suggest it may offer short-term immunity against a range of viral and certain bacterial infections, raising the prospect of a single seasonal vaccine for common colds, influenza and other respiratory illnesses. For those of us working in the prevention and control of waterborne pathogens, the natural question follows: if such a vaccine can reduce bacterial pneumonia, could it one day lessen the burden of Legionnaires’ disease as well?
In this article, we examine how the proposed universal vaccine differs from traditional pathogen-specific immunisation, the science underpinning its reported success in animal models, and what this might mean for respiratory infections more broadly. We also consider the important distinctions between gram-positive and gram-negative bacteria, explore whether protection demonstrated against organisms such as Staphylococcus aureus could extend to Legionella, and assess the practical realities of seasonality, transmission routes and ongoing risk management. While vaccination may offer hope for the future, effective control of engineered water systems remains central to preventing cases of Legionnaires’ disease today.
A version of this article highlighting the work by scientists at Stanford University involving the development of a universal vaccing for respiratory illnesses first appeared in Legionella Control International’s newsletter. To get it in your inbox, sign up here.
Is universal protection from respiratory infections now a possibility?
We’re all familiar with the dreaded common cold. While it may not be severe, it can make us feel low, with headaches, sniffles, and sneezing making regular appearances until the germs leave us. Beyond that, there’s influenza – or flu – which can put the worst affected people in hospital. And in both cases, they’re easy to spread to other people around us.
Yet this could soon be a thing of the past if researchers at Stanford University in the US have anything to do with it.
In mid-February 2026, they revealed they had been testing a so-called ‘universal vaccine’ … a vaccine that is potentially capable of providing protection against respiratory conditions including the common cold, flu, and even coughs. They have tested this universal vaccine on animals and noted positive results that lasted for approximately three months. They have not yet tested the vaccine on humans, although that would likely be the next step.
What is a universal vaccine?
A universal vaccine is the term the researchers have come up with to describe how the potential vaccine might work.
Traditionally, a vaccine is developed to combat a specific virus or bacterium. These are also known as pathogens. The vaccine introduces the virus or bacterium in question into the body in a safe way. It will either be dead or weak, so unable to cause illness.
The body then develops antibodies to combat that pathogen. The COVID-19 vaccine was produced in this way. It meant that if we had the vaccine and then encountered COVID-19 in the future, our bodies would be able to fight it, and we would either sidestep feeling ill or get a mild version of the disease.
How does this universal vaccine work?
The idea behind a universal vaccine is that it could protect against multiple respiratory pathogens. Stanford University researchers tested their vaccine on mice, using it in the form of a nasal spray. Results indicated that the mice were then protected against a range of respiratory infections caused by viruses and certain forms of bacteria. This effect lasted for approximately three months.
Whereas traditional vaccines prepare the immune system to combat a specific virus or bacterium, the universal vaccine idea aims to replicate the way immune cells communicate. In doing so, those cells can combat a range of illnesses and infections instead of only one.
When we are infected by a virus or bacterium, our immune system kicks in. If we have had a vaccine to prevent the illness caused by a specific virus or bacterium, we might avoid being ill or be only mildly affected. For instance, the flu vaccine provides protection against the most likely forms of flu to be present in a particular year. You may still catch flu, but you’re far less likely to be seriously affected by it.
With this universal vaccine, we may eventually reach the stage where one vaccine is enough to prevent all winter colds, flu viruses, and other respiratory infections. Our immune system would recognise that it is under attack and prevent any illness from occurring.
Can it protect against pneumonia?
The team noted that they had proved the vaccine protects against infections caused by Staphylococcus aureus, which causes pneumonia and skin infections among other things.
And that could be potentially interesting when it comes to Legionnaires’ disease and its cause, Legionella bacteria.
Could a universal vaccine also provide protection against Legionnaires’ disease?
This immediately came to mind when we read about the progress made towards creating a respiratory related universal vaccine that would be suitable for humans. We know that researchers confirmed the vaccine provided protection against infection caused by Staphylococcus aureus, a gram-positive bacterium in the Bacillota family.
In contrast, Legionella is a gram-negative bacteria discovered a few years after an outbreak of a form of pneumonia in 1976 that was eventually called Legionnaires’ disease. The name was selected because the bacterium caused a serious outbreak at a hotel where a Legionnaires’ convention was being held. It affected many older people, affecting 182 people in all and leading to the deaths of 29 individuals.
If the universal vaccine has proven successful in preventing illness caused by various bacteria thus far, could it also prevent people falling ill with Legionnaires’ disease after being exposed to Legionella bacteria? This is certainly our hope.
Asking a seasonal question
Researchers are delighted with the results thus far, and they should be. Of course, there is still much work to be done, including testing the vaccine on humans to see whether similar results are achieved.
However, let us assume for a moment that things go well and we do eventually get a universal vaccine offered each year. The idea of a seasonal vaccine that would provide protection against seasonal flu, coughs, colds, and other bacterial lung infections could certainly relieve pressure on the NHS. It would also be likely to ease the pressure on businesses coping with workers being out sick.
A seasonal vaccine would not protect against all cases of Legionnaires’ disease though, if the vaccine was found to protect against this illness as well. Legionella spreads through contaminated mist or water vapour suspended in the air.
Indeed, cases of Legionnaires’ disease tend to be more common during the warmer months. Legionella bacteria prefer a temperature range of between 20-45 degrees Celsius, a range easier to achieve during the summer than the winter. In this case, a seasonal universal vaccine would likely be given outside the key period of the year for Legionella bacterial lung infections.
In conclusion
Clearly, there is still plenty of research to be done, but the potential that we might have a universal vaccine available in a few years from now is exciting. If it can prevent bacterial lung infections, there is a chance that it may reduce cases of Legionnaires’ disease as well among those who are given the vaccine.
We will be watching this story closely as it develops. It is unclear when any human trials might take place, but hopefully they will provide evidence of protection in those who take the vaccine.
Proactive Legionella management, monitoring, and compliance
While the prospect of a universal respiratory vaccine is undoubtedly exciting, it does not remove the need for robust, evidence-based control of water systems. Even if future immunisation strategies were shown to reduce susceptibility to certain bacterial pneumonias, Legionella Control International recognises that prevention of Legionnaires’ disease must continue to focus on proactive risk management, rigorous monitoring, and strict compliance with current guidance and legislation. Vaccination, should it become available, would complement, not replace the essential measures required to control Legionella bacteria in engineered water systems.
As a world-leading water safety specialist, Legionella Control International supports duty holders and responsible persons in managing Legionella and other waterborne pathogens across workplace environments. Our experienced water safety teams assist organisations with the development of water safety management teams, policies and procedures, particularly across large-scale and multi-site property portfolios, complex facilities and higher-risk settings. We also provide specialist risk assessments, independent auditing, training and ongoing technical support to help safeguard staff, visitors and building users.
If you have any concerns relating to Legionella control or would like to speak with one of our healthcare water specialists, please contact our team on 0330 223 36 86.
